📇 Rhumatologue · MULHOUSE CEDEX 1 · (68) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
31 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
110.1 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
HOPITAL DU HASENRAIN
87 AV D'ALTKIRCH BP 1070, 68051 MULHOUSE CEDEX 1
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Environmental science and pollution research international · 2025
Environmental science and pollution research international · 2022
Stem cells translational medicine · 2021
Abstract Buerger's disease or thromboangiitis obliterans is a type of obstructive vascular diseases categorized as vasculitis and usually present in 95% of young smoker men. The main pathogenetic mechanism is interplay between immune system and inflammation. Earlier our phase II study has shown that Stempeucel is safe when injected at 2 million cells/kg body weight by virtue of its anti-inflammatory, immunomodulatory, and angiogenetic properties. The present study was conducted to further assess the safety and efficacy of Stempeucel in critical limb ischemia due to Buerger's disease after obtaining approval from Indian FDA based on the data generated in the phase II study. This is an open label, multicenteric phase IV PMS study conducted across India with experienced vascular surgeons. Fifty patients of critical limb ischemia due to Buerger's disease with Rutherford III-5 or III-6 were included in the study and each individual received a dose of 2 million cells/kg body weight of Stempeucel in the calf muscles and around the ulcer. These patients were evaluated over 12 months from drug administration. The present study showed the continued long term efficacy over a period of 12 months follow up in these patients corroborating the result obtained in the previous phase II studies. There was significant improvement in rest pain, ankle systolic pressure, and ankle brachial pressure index with accelerated ulcer healing. In conclusion, the present study shows that the intramuscular administration of Stempeucel continues to be safe, tolerable, and effective alternative treatment in patients with Buerger's disease.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Environmental science and pollution research international · 2025 · Journal Article
Tournebize J, Bedos C, Corio-Costet MF, Douzals JP, et al.
Environmental science and pollution research international · 2025 · Journal Article
Amichot M, Bertrand C, Chauvel B, Corio-Costet MF, et al.
Environmental science and pollution research international · 2025 · Journal Article
Mamy L, Pesce S, Sanchez W, Aviron S, et al.
Environmental science and pollution research international · 2024 · Journal Article
Doussan I, Barthélémy C, Berny P, Bureau-Point E, et al.
Environmental science and pollution research international · 2022 · Journal Article
Larras F, Charles S, Chaumot A, Pelosi C, et al.
Archives of gerontology and geriatrics · 2021 · Journal Article
M R, M A, H B, M O
The Journal of international medical research · 2026 · Journal Article
Been Sayeed SKJ, M M, Mahmud R, Rahman S, et al.
Bioinformation · 2025 · Journal Article
G N, M SSL, V S, K S, et al.
Brain, behavior, & immunity - health · 2023 · Journal Article
Graïc JM, Finos L, Vadori V, Cozzi B, et al.
PLoS neglected tropical diseases · 2023 · Journal Article
Guttapadu R, Prakash N, M A, Chatterjee R, et al.
Clinical rheumatology · 2025 · Journal Article
Mohan A, Mohan A, Ramachandran A, Pulinilkunnathil JG, et al.
Virus evolution · 2024 · Journal Article
Courcelle M, Salami H, Tounkara K, Lo MM, et al.
European journal of medical genetics · 2022 · Journal Article
Laetitia MM, Veronique K, Mamy NZ, Cathy SM, et al.
Clinical rheumatology · 2025 · Journal Article
A K, M EA, M H, H A, et al.
Rheumatology and immunology research · 2024 · Journal Article
Datta D, Khatun M, Bankura B, Sarkar M, et al.
JACC. Case reports · 2024 · Case Reports
Kharge JL, M UK, M L J, Newaskar AA, et al.
Stem cells translational medicine · 2021 · Clinical Trial, Phase IV
Gupta PK, Dutta S, Kala S, Nekkanti M, et al.
Cureus · 2024 · Case Reports
Surapaneni D, Dasi SC, Sam N, M J
JMIR research protocols · 2025 · Journal Article
M A, Ahmad A, A A, Raj LS, et al.
Physiotherapy · 2026 · Letter
Rashid FA, M RP
Ecology and evolution · 2025 · Journal Article
Bersacola E, McLennan MR, Bessa JH, Camara H, et al.
The Journal of the Association of Physicians of India · 2022 · Journal Article
Murugesan H, Cs G, Nasreen HS, Santhanam S, et al.
BMJ case reports · 2025 · Journal Article
Pathrot D, Nachappa AA, Mannual S, M SK
Indian journal of dermatology, venereology and leprology · 2023 · Letter
Rao AG, M N, Ch S, Jhawar J
Radiology case reports · 2023 · Case Reports
Lee ZR, Lai YK, M L, Khor LY, et al.
Cureus · 2025 · Journal Article
Nallaperumal S, V P, M C V, Pusapati LCV, et al.
The Science of the total environment · 2022 · Journal Article
Larras F, Beaudouin R, Berny P, Charles S, et al.
Cureus · 2022 · Case Reports
Chandra MS, G A M, M RK
Cureus · 2024 · Case Reports
Mohan A, Kuriakose SM, James L, G BT, et al.
Cureus · 2023 · Journal Article
M D, Kumar J, Ramalingam K
medRxiv : the preprint server for health sciences · 2022 · Preprint
Ghosh P, Niesen MJM, Pawlowski C, Bandi H, et al.